CART-19 Post-ASCT for Multiple Myeloma

• Sponsor: University of Pennsylvania (Other)
• Overall Status: Terminated
• CT.gov ID: NCT02794246
• Collaborator: (none)
• Enrollment: 6
• Location: 1
• Arm: 1
• Actual Duration (Months): 35
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This will be a single-arm, open-label study. Patients will be enrolled during induction therapy for multiple myeloma, prior to standard-of-care consolidation with autologous stem cell transplantation (ASCT). T cells will be harvested for T cell manufacturing prior to ASCT, and CART-19 will be infused at day ~60 post-ASCT, 3 days after lymphodepleting chemotherapy. The primary endpoint is progression-free survival (PFS) after ASCT. As detailed below, the study is powered to detect an increase in two-year PFS to ~75% from a baseline expectation of 55% based on historical data. Secondary endpoints will evaluate CART-19 persistence and function, minimal residual disease, immune correlative endpoints, and associations of progression-free survival (PFS) with CART-19 persistence and clinical and biologic characteristics of multiple myeloma.

Condition or Disease	Intervention/Treatment	Phase
Multiple Myeloma	Biological: CART-19 cells	Phase 2

Study Design

• Study Type: Interventional
• Actual Enrollment: 6 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase 2 Study Of Autologous T Cells Engineered To Express an Anti-CD19 Chimeric Antigen Receptor (CART-19) Following First-line Autologous Stem Cell Transplantation for High-risk Multiple Myeloma
• Actual Study Start Date: Jun 1, 2016
• Actual Primary Completion Date: Feb 1, 2019
• Actual Study Completion Date: May 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Single Arm	Biological: CART-19 cells

Outcome Measures

Primary Outcome Measures

1. Evaluate Progression Free Survival [Follow progression-free survival (PFS) for 2-3 years post CART-19 infusion]

   Progression free survival as defined by Partial Response (PR); Stable Disease (SD); Very Good Partial Response (VGPR), and Stringent Complete Response (sCR) to treatment. The outcome measures range from Stable disease to Stringent Complete Response (SD worst outcome; sCR best outcome

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 70 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Subjects must be age 18-70, inclusive, at time of enrollment.

• Subjects must have ECOG performance status of 0-2.

• Subjects must have a confirmed diagnosis of active multiple myeloma according to IMWG criteria, summarized below in Table 6. For circumstances not encompassed by this summary of the diagnostic criteria, reference can be made to the full publication of the IMWG criteria67. In addition, subjects must have "high-risk" multiple myeloma according to one of the following criteria:

1. Any of the following high-risk cytogenetic features, documented by FISH or metaphase karyotyping: deletion 17p, t(4;14), t(14;16), t(14;20).

2. Standard-risk cytogenetics but elevated LDH and beta-2-microglobulin > 5.5 mg/L (i.e., R-ISS stage III).

• At time of enrollment, subjects must be within 9 months of initiation of systemic therapy for multiple myeloma.

• Requirements for pre-enrollment therapy: Subjects must have received or be receiving, at time of enrollment, "RVD" therapy (combination therapy with lenalidomide, bortezomib, and dexamethasone). Patients must have received ≤6 cycles of RVD at time of enrollment and must not have progressed (by IMWG criteria65) on RVD. Patients may have received other regimens prior to RVD if such therapy was limited to ≤3 cycles. Patients may have received radiation therapy prior to enrollment. Patients must not have received infusional chemotherapy (e.g., VTD-PACE or similar regimen) prior to enrollment.

• Subjects must be eligible for ASCT and to receive a melphalan dose of 200 mg/m2 as defined by the following criteria:

1. Left ventricular ejection fraction ≥ 40%,

2. AST/ALT ≤2.5 times the upper limit of normal

3. Total bilirubin ≤1.5 mg/dL, unless hyperbilirubinemia is attributable solely to Gilbert's syndrome.

4. Estimated (by CKD-EPI or Cockgroft-Gault equations) or calculated CrCl ≥40 ml/min.

5. DLCO ≥50% of predicted after correction for anemia.

• Subjects must have measurable disease by standard serum and urine tests to enable post-transplant monitoring for progression-free survival. Any of the following criteria are sufficient to define measurable disease.

1. Serum M-spike ≥ 0.5 g/dL

2. 24 hr urine M-spike ≥ 200mg

3. Involved serum FLC ≥ 50 mg/L with abnormal ratio

4. For IgA multiple myeloma, total serum IgA level elevated above normal range. Note: Measurable disease does not need to be documented at enrollment but can be based on historical lab results obtained at or since diagnosis with multiple myeloma. For example, a patient who does not have measurable disease at enrollment due to complete remission after induction therapy is eligible if the disease was previously measurable by one of the above criteria.

• Subjects must have signed written, informed consent.

• Subjects of reproductive potential must agree to use acceptable birth control methods

Exclusion Criteria:

• Subjects must not:

Be pregnant or lactating. Have inadequate venous access for or contraindications to leukapheresis. Have any active and uncontrolled infection. Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined.

Have NYHA Class III or IV heart failure (see Appendix 2), unstable angina, or a history of recent (within 6 months) myocardial infarction or sustained (>30 seconds) ventricular tachyarrhythmias.

Have undergone allogeneic stem cell transplantation. Have received prior gene therapy or gene-modified cellular immunotherapy. Have active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy.

Have prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma. Screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms are present.

Have a contraindication to post-ASCT maintenance lenalidomide. Have active infection with HIV (negative HIV 1/2 antibody screen), hepatitis C (negative hepatitis C antibody screen), or hepatitis B (negative hepatitis B surface antigen). Any positive serologies for HIV or viral hepatitis should be confirmed with appropriate confirmatory testing before concluding that an active infection is present. Subjects with positive hepatitis core antibody are also excluded since the effect of long-term B cell depletion on the risk of hepatitis B reactivation is unknown.

Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania	United States	19104

Sponsors and Collaborators

• University of Pennsylvania

Investigators

• Principal Investigator: Alfred Garfall, MD, Abramson Cancer Center of the University of Pennsylvania

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Apr 11, 2017

More Information

Publications

None provided.

• Responsible Party: University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT02794246
• Other Study ID Numbers: UPCC 19416, 824655
• First Posted: Jun 9, 2016
• Last Update Posted: Apr 2, 2020
• Last Verified: Feb 1, 2020

• Additional relevant MeSH terms: Multiple Myeloma; Neoplasms, Plasma Cell

Study Results

Participant Flow

Arm/Group Title	CART-19 Cells
Arm/Group Description	single infusion of 1-5x10E8 cells CART-19 cells
Period Title: Overall Study
STARTED	6
Treated	3
COMPLETED	0
NOT COMPLETED	6

Baseline Characteristics

Arm/Group Title	Single Arm
Arm/Group Description	CART-19 cells
Overall Participants	6
Age (Count of Participants)
<=18 years	0 0%
Between 18 and 65 years	5 83.3%
>=65 years	1 16.7%
Sex: Female, Male (Count of Participants)
Female	3 50%
Male	3 50%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	0 0%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	6 100%
More than one race	0 0%
Unknown or Not Reported	0 0%
Region of Enrollment (participants) [Number]
United States	6 100%

Outcome Measures

1. Primary Outcome

Title	Evaluate Progression Free Survival
Description	Progression free survival as defined by Partial Response (PR); Stable Disease (SD); Very Good Partial Response (VGPR), and Stringent Complete Response (sCR) to treatment. The outcome measures range from Stable disease to Stringent Complete Response (SD worst outcome; sCR best outcome
Time Frame	Follow progression-free survival (PFS) for 2-3 years post CART-19 infusion

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Single Arm
Arm/Group Description	CART-19 cells
Measure Participants	6
Stable Disease	1 16.7%
Partial Response	3 50%
Very Good Partial Response	1 16.7%
Stringent Complete Response	1 16.7%

Adverse Events

Time Frame	18 months
Arm/Group Title	Single Arm
Arm/Group Description	CART-19 cells
All Cause Mortality
	Single Arm
	Affected / at Risk (%)	# Events
Total	0/6 (0%)
Serious Adverse Events
	Single Arm
	Affected / at Risk (%)	# Events
Total	2/6 (33.3%)
Immune system disorders
Cytokine release syndrome	1/6 (16.7%)	1
Infections and infestations
Upper respiratory infection	1/6 (16.7%)	1
Other (Not Including Serious) Adverse Events
	Single Arm
	Affected / at Risk (%)	# Events
Total	1/6 (16.7%)
Blood and lymphatic system disorders
Anemia	1/6 (16.7%)	1
Cardiac disorders
Sinus tachycardia	1/6 (16.7%)	1
Immune system disorders
Cytokine release syndrome	1/6 (16.7%)	1
Investigations
Platelet count decreased	1/6 (16.7%)	1
Neutrophil count decreased	1/6 (16.7%)	1
White blood cell decreased	1/6 (16.7%)	1
Metabolism and nutrition disorders
Hypokalemia	1/6 (16.7%)	1
Hypocalcemia	1/6 (16.7%)	1
Hypoalbuminemia	1/6 (16.7%)	1
Hypophosphatemia	1/6 (16.7%)	1
Skin and subcutaneous tissue disorders
Pruritus	1/6 (16.7%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.